Restoration of deficient IL-15 signaling enhances innate lymphoid cell immunity in brain metastasis

McMullen, T. P.; Naef, P.; Zagni, E.; Tian, L.; Zhao, E.; Wechter, N.; Longworth, A. J.; Adam, I.; Insua-Rodriguez, J.; Savage, H.; Hur, I.; Garcia, S. A.; Ma, D.; Liew, M. H.; Mallya, S.; Kessenbrock, K.; O'Sullivan, T. E.; Mohyeldin, A.; Yu, J.; Lawson, D. A.

doi:10.64898/2026.10.02.756334

Home/Archive/bioRxiv

bioRxiv · 10.64898/2026.10.02.756334

Restoration of deficient IL-15 signaling enhances innate lymphoid cell immunity in brain metastasis

View original source ↗Export metadata ↓

Abstract

Natural killer (NK) cells and type 1 innate lymphoid cells (ILC1s), collectively known as group 1 innate lymphoid cells (ILCs), are critical mediators of anti-tumor immunity, yet their role in brain metastasis remains poorly defined. Using single-cell RNA sequencing and functional depletion models, we show that group 1 ILCs fail to provide adequate tumor control in breast cancer brain metastasis (BCBM). In contrast to the liver, where diverse, functionally competent group 1 ILC populations facilitate excellent metastatic control, group 1 ILCs in BCBM show limited diversity and profound tissue-specific dysfunction such that their depletion had no effect on tumor burden despite modest parenchymal infiltration. We attribute this group 1 ILC dysfunction to severely restricted IL-15 availability, with IL-15R protein detected at 500-fold lower concentration in the brain than in the liver. Local IL-15 complex administration restored group 1 ILC accumulation, cytotoxicity, and tissue residency, significantly reducing brain metastatic burden independent of T cells. Intracranial delivery of IL-15-secreting induced pluripotent stem-cell-derived (iPSC)-NK cells, already in clinical testing for non-small cell lung cancer, significantly reduced tumor burden. Collectively, these findings reveal how tissue-specific differences in cytokine availability shape group 1 ILC population diversity and disease response, establishing localized IL-15 signaling as a compelling strategy to unlock innate immunity against intracranial malignancies.

Explore related subjects

immunology Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

McMullen, T. P., Naef, P., Zagni, E., Tian, L., Zhao, E., Wechter, N., Longworth, A. J., Adam, I., Insua-Rodriguez, J., Savage, H., Hur, I., Garcia, S. A., Ma, D., Liew, M. H., Mallya, S., Kessenbrock, K., O'Sullivan, T. E., Mohyeldin, A., Yu, J., Lawson, D. A.. 2026-10-10. Restoration of deficient IL-15 signaling enhances innate lymphoid cell immunity in brain metastasis. https://doi.org/10.64898/2026.10.02.756334

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Stealth CAR-Tregs evade CD3 antibody therapy and skew immune responses toward regulation

Organ transplantation standard of care relies on lifelong immunosuppression, increasing infection and malignancy risks. An emerging approach using Chimeric Antigen Receptor Regulatory T cells (CAR-Tregs) targeting donor antigens, allows the suppression of alloimmune responses while preserving protective immunity. However, transplant recipients harbor a substantial pool of alloreactive memory T-cells, limiting CAR-Tregs tolerance-promoting effect. To address this challenge, our strategy combines selective depletion of activated T-cells, using non-mitogenic CD3 antibody therapy, with HLA-A2-targeted-CAR-Treg therapy. We established that T-cell receptor alpha chain (TRAC) deletion does not impair CAR-Treg antigen-specific activation, expansion, or their transcriptomic, phenotypic, epigenetic, and functional profiles. TRAC-/-CAR-Tregs exhibit robust protection from CD3 antibody depletion in circulation and peripheral tissues, whereas most TRAC+/+CAR-T cells are eliminated. Importantly, TRAC+/+CAR-T cells that escape CD3 antibody mediated depletion exhibit a transcriptomic signature consistent with T-cell exhaustion. Our findings demonstrate that CD3 antibody therapy provides an in vivo survival advantage to TRAC-/-CAR-Tregs, thereby shifting the immune balance toward regulation. This approach might enhance the translational potential of CAR-Treg therapy by reducing the required cell dose needed for clinical efficacy.

immunology↗

bioRxiv2026

Glucose restriction reduces systemic, but not cardiac, inflammation during neonatal sepsis in preterm pigs

Introduction: Preterm infants are highly susceptible to sepsis and hyperglycemia may exacerbate inflammation and worsen outcomes. We examined how glucose provision influences systemic and cardiac responses during neonatal sepsis in preterm pigs. Methods: Preterm piglets (90 % gestation) were infused with Staphylococcus epidermidis to induce sepsis. In Experiment 1, three ventilated and anesthetized piglets were continuously monitored for mean arterial pressure (MAP) and blood gases to characterize acute cardiovascular and metabolic deterioration. In Experiment 2, thirty-three piglets were randomized to standard (14 g/kg/day) or reduced (3.5 g/kg/day) glucose provision, with or without infection, and followed for 20h. Results: Infection in Experiment 1 caused progressive hypotension, acidosis, and hypoxia, mirroring clinical neonatal sepsis. In Experiment 2, reduced glucose provision improved survival (77 % vs 46 %, p = 0.06) and attenuated systemic inflammation, with lower IL-6 and higher IL-10 concentrations. Infection induced mild cardiac neutrophil infiltration, without affecting plasma troponin T but clearly reduced cardiomyocyte mitotic density and triggered upregulation of inflammatory transcriptional pathways (NF-{kappa}B, JAK-STAT) and suppression of oxidative phosphorylation. In infected animals. glucose restriction preserved cardiomyocyte mitotic density but did not alter cardiac structure, injury markers or gene expression. Conclusion: Neonatal infection induced circulatory failure, suppression of cardiomyocyte proliferation and upregulation of inflammatory genes in cardiac tissue, while reduced glucose provision mitigated systemic immune responses and preserved cardiomyocyte proliferation.

immunology↗

bioRxiv2026

The increased production of monocytes with immunosuppressive transcriptional profiles predicts the development of SIV encephalitis

HIV-associated neurocognitive disorders (HAND) remain common despite antiretroviral therapy. We previously demonstrated that increased percentages of newly generated BrdU-labeled (BrdU+) monocytes predict AIDS progression and SIV encephalitis (SIVE) as early as 8 and consistently by 21 days post-infection (DPI) in SIV-infected macaques, but their molecular identity remained unknown. We performed Bulk RNA sequencing of FACS-sorted BrdU+ and BrdU- monocytes from uninfected animals and SIV-infected macaques at 21 DPI and necropsies, including SIVE or not (SIVnoE). BrdU+ monocytes underwent progressive transcriptional remodeling during SIV infection. Early SIVE-predictive monocytes exhibited suppressed interferon, TNF-/NF-{kappa}B, antigen-presentation, and antimicrobial pathways, with increased LILRB4 and PARP2 expression. At terminal disease, SIVE BrdU+ monocytes displayed an immunosuppressive profile, reduced HLA-DR expression, and increased structural variants compared with SIVnoE monocytes. Together, newly generated circulating monocytes in animals progressing to SIVE are an immature and immunosuppressive population that emerges before neuropathology, implicating dysregulated monocytopoiesis and pathogenic monocytes in HAND.

immunology↗